Focus on Rx and OTC Cough/Cold Products
The Rx cough market is about 25 million prescriptions per year. There are significant unmet needs in the Rx market, particularly the non-narcotic segment. Recent concerns about abuse and overdose associated with narcotics have produced some dramatic shifts in the cough market.
Ten years ago, the Rx cough market was about evenly divided between codeine and hydrocodone based products. As the chart below shows, prescriptions for hydrocodone have fallen with significant gains by benzonatate, the only non-narcotic Rx cough product.
It is our core belief that the prescription cough market is large and underserved with significant opportunities for new products, particularly for oral tablet formulations, narcotic options with Abuse Deterrent formulations and non-narcotic products with patent protection.
We believe the opportunity for our prescription cough products will compete in a market valued at $3 billion at branded prices. Based on most recent data, non-narcotic prescription cough products like benzonatate have surpassed narcotic prescribing. This is positive news as Alitair has a very strong patent portfolio around our benzonatate formulation as the chart below shows. Alitair uniquely has a portfolio of oral tablet non-narcotic and narcotic options for physicians and patients seeking relief from severe cough.
Alitair’s development strategy emphasizes speed, low research & development costs, and efficient regulatory and marketing strategies. Alitair has had 6 pre-IND meetings with the FDA. These meetings were used to gain valuable insights into FDA’s view of the proposed development path. As a result of these meetings, Alitair can develop its products using the 505(b)(2) route.
We believe the opportunity for benzonatate is significant and could provide an opportunity to grab a significant revenue share of this market. Alitair also has a very strong patent portfolio around our benzonatate formulation as the chart below shows.